X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trade higher on Wednesday as investors gear up for new results from a Phase 3 trial of its oral cxcr4 antagonist, mavorixafor, for treatment of patients with WHIM syndrome.
The firm will present new data at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St. Louis.
Shares of X4 climbed nearly 14% on Wednesday morning to trade around US$1.09.
New data will focus on additional secondary endpoints, including the impact of oral, once-daily mavorixafor on the rate, severity, and duration of infections, among other outcomes metrics, as measured during the 52-week trial period, according to X4.
The company will also provide an update on its US regulatory activities in support of its potential New Drug Application-submission for mavorixafor, which is expected early in the second half of 2023.
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare, inherited, combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4/CXCL12 pathway.
Symptoms include frequent, recurrent infections with a high risk of lung disease, refractory warts from underlying human papillomavirus (HPV) infection, limited antibody production due to low levels of immunoglobulin, and an increased risk of developing certain types of cancer.
In other news, B Riley (NASDAQ:RILY) Securities maintained coverage of X4 Pharmaceuticals with a Buy recommendation.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas